FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367721070> ?p ?o ?g. }

• W4367721070 abstract "<h3>Background and Importance</h3> The European Society for Medical Oncology – Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a tool designed to evaluate the clinical benefit of cancer treatments and can facilitate decision-making. <h3>Aim and Objectives</h3> To analyse which of the cancer treatments started providing a substantial magnitude of clinical benefit according to the ESMO-MCBS. Know the prevalence of patients who have started some low benefit treatment. Assess whether the ESMO-MCBS could be a good indicator of the prescription’s quality. <h3>Material and Methods</h3> Retrospective observational study that included all cancer treatments that were started in a tertiary care hospital from 03/01/22 to 06/30/22. The variables were collected: patient, treatment(s) prescribed, indication and ESMO-MCBS rating. The ESMO-MCBS score is considered in two different therapeutic settings: potentially curative treatments (A, B and C) and non-curative treatments (1 to 5). Substantial magnitude of clinical benefit was graded as A, B, 5 and 4. The variables calculated were:% of treatments with scores of greater clinical benefit and% of patients with at least one treatment of low benefit. <h3>Results</h3> A total of 245 starts of treatment were reviewed, of which only 75 (31%) had an ESMO-MCBS rating. In 63% of the cases (n=47), treatments considered to be of relevant clinical benefit were started. Of these, 3 (6%) were treatments with curative intent (all level A) and 44 (94%) with palliative intent (level 4–5). Of those rated at level 4–5, pembrolizumab (n=14; 32%) in non-small-cell lung cancer and nivolumab (n=4; 9%) in head-neck cancer were predominant. 37% (n=28) of the patients started some low benefit treatment (level 1–3), being the most frequent atezolizumab (n=5; 18%) in small-cell lung cancer and nab-paclitaxel (n=5; 18%) in pancreatic adenocarcinoma. <h3>Conclusion and Relevance</h3> More treatments with substantial benefit are started than those with less clinical benefit. All treatments with curative intent were level A. The non-curative setting presents a greater number of treatments with doubtful benefit. For most of the treatments classified as low benefit, there is no better therapeutic alternative, so we cannot assume that it is an indicator of poor prescription. Furthermore, we cannot classify most treatments because many of them do not have an ESMO-MCBS classification assigned. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4367721070 created "2023-05-04" @default.
• W4367721070 creator A5000799305 @default.
• W4367721070 creator A5006026248 @default.
• W4367721070 creator A5008804229 @default.
• W4367721070 creator A5028093602 @default.
• W4367721070 creator A5045866975 @default.
• W4367721070 creator A5090991298 @default.
• W4367721070 date "2023-03-01" @default.
• W4367721070 modified "2023-09-26" @default.
• W4367721070 title "4CPS-221 Assessment of clinical benefit of cancer treatments according to the European society for medical oncology scale" @default.
• W4367721070 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.421" @default.
• W4367721070 hasPublicationYear "2023" @default.
• W4367721070 type Work @default.
• W4367721070 citedByCount "0" @default.
• W4367721070 crossrefType "proceedings-article" @default.
• W4367721070 hasAuthorship W4367721070A5000799305 @default.
• W4367721070 hasAuthorship W4367721070A5006026248 @default.
• W4367721070 hasAuthorship W4367721070A5008804229 @default.
• W4367721070 hasAuthorship W4367721070A5028093602 @default.
• W4367721070 hasAuthorship W4367721070A5045866975 @default.
• W4367721070 hasAuthorship W4367721070A5090991298 @default.
• W4367721070 hasBestOaLocation W43677210701 @default.
• W4367721070 hasConcept C121608353 @default.
• W4367721070 hasConcept C126322002 @default.
• W4367721070 hasConcept C138496976 @default.
• W4367721070 hasConcept C143998085 @default.
• W4367721070 hasConcept C15744967 @default.
• W4367721070 hasConcept C159110408 @default.
• W4367721070 hasConcept C167135981 @default.
• W4367721070 hasConcept C177713679 @default.
• W4367721070 hasConcept C23131810 @default.
• W4367721070 hasConcept C2426938 @default.
• W4367721070 hasConcept C2776598537 @default.
• W4367721070 hasConcept C2779951463 @default.
• W4367721070 hasConcept C71924100 @default.
• W4367721070 hasConcept C83849319 @default.
• W4367721070 hasConcept C98274493 @default.
• W4367721070 hasConceptScore W4367721070C121608353 @default.
• W4367721070 hasConceptScore W4367721070C126322002 @default.
• W4367721070 hasConceptScore W4367721070C138496976 @default.
• W4367721070 hasConceptScore W4367721070C143998085 @default.
• W4367721070 hasConceptScore W4367721070C15744967 @default.
• W4367721070 hasConceptScore W4367721070C159110408 @default.
• W4367721070 hasConceptScore W4367721070C167135981 @default.
• W4367721070 hasConceptScore W4367721070C177713679 @default.
• W4367721070 hasConceptScore W4367721070C23131810 @default.
• W4367721070 hasConceptScore W4367721070C2426938 @default.
• W4367721070 hasConceptScore W4367721070C2776598537 @default.
• W4367721070 hasConceptScore W4367721070C2779951463 @default.
• W4367721070 hasConceptScore W4367721070C71924100 @default.
• W4367721070 hasConceptScore W4367721070C83849319 @default.
• W4367721070 hasConceptScore W4367721070C98274493 @default.
• W4367721070 hasLocation W43677210701 @default.
• W4367721070 hasOpenAccess W4367721070 @default.
• W4367721070 hasPrimaryLocation W43677210701 @default.
• W4367721070 hasRelatedWork W2164009748 @default.
• W4367721070 hasRelatedWork W2313076522 @default.
• W4367721070 hasRelatedWork W2765980456 @default.
• W4367721070 hasRelatedWork W2976382042 @default.
• W4367721070 hasRelatedWork W2981703979 @default.
• W4367721070 hasRelatedWork W3013145321 @default.
• W4367721070 hasRelatedWork W3208090289 @default.
• W4367721070 hasRelatedWork W3210359220 @default.
• W4367721070 hasRelatedWork W4367672288 @default.
• W4367721070 hasRelatedWork W2464797648 @default.
• W4367721070 isParatext "false" @default.
• W4367721070 isRetracted "false" @default.
• W4367721070 workType "article" @default.